449 TOWARDS THE DEVELOPMENT OF A THERAPEUTIC VACCINE TO TREAT CHRONIC HBV INFECTION: AD5-BASED VACCINES ENCODING MULTIPLE HBV ANTIGENS INDUCE STRONG T-CELL RESPONSES IN PRE-CLINICAL MODELS

P =0.0049; A vs C P < 0.0001; B vs C P =0.0001). Forty seven percent of patients in group A and B were HLA-A2 positive. Tim-3/PD-1 HBV-specific CD8 T cells were 61.95% (median, range 18.7%-95.5%), Tim-3/PD-1 were 3.135% (median, range 0.00–43.6%) and Tim-3/PD-1 were 16.6% (median, range 3.37%70.2%). The frequency of Tm-3/PD-1 HBV-specific CD8 T cells in ACLF (69.1%±17.71%) were significantly higher than that in CHB (56.33%±19.74%, P =0.0112). The level of IFN-g in PBMC culture medium had no statistical differences in ACLF (median 306.1 pg/ml) and CHB (median 302.1 pg/ml). Conclusions: Tim-3 and PD-1 expressions were significantly upregulated in patients with HBV infection, especially in ACLF patients. The majority of HBV-specific CD8 T cells coexpressed Tim-3 and PD-1, which may be play an important role in HBV infection persistent and pathogenesis of liver damage in patients with HBV chronic infection.